INCRUSE ELLIPTA
Prescription medicines
INCRUSE ELLIPTA
Product information:
INCRUSE ELLIPTA product monograph (PDF - 847 KB)
Patient information:
Important information (PDF - 581 KB) for patients
×
Where we operate
You are currently visiting our Canada website.
- Global https://www.gsk.com
- Africa
-
Asia & the Middle East
- Bangladesh (EN)
- Cambodia (EN)
- China (Mainland) (ZH/EN)
- Egypt (EN/AR)
- Hong Kong and Macau (EN/ZH)
- India (EN)
- Indonesia (EN)
- Israel (EN)
- Japan (JP)
- Kazakhstan (RU)
- Korea (KO)
- Malaysia (EN)
- Myanmar (EN)
- Pakistan (EN/UR)
- Philippines (EN)
- Saudi Arabia (EN)
- Singapore (EN)
- Sri Lanka (EN)
- Taiwan (ZH)
- Thailand (EN)
- Turkey (TR)
- United Arab Emirates (EN)
- Vietnam (EN)
- Australasia
-
Europe
- Albania (EN)
- Austria (DE)
- Belarus (EN)
- Belgium (FR/NL/EN)
- Bosnia and Herzegovina (EN)
- Bulgaria (BG)
- Croatia (EN)
- Cyprus (EN)
- Czech Republic (CS)
- Denmark (DA)
- Estonia (EN)
- Finland (FI)
- France (FR)
- Germany (DE)
- Greece (EL)
- Hungary (HU)
- Ireland (EN)
- Italy (IT)
- Latvia (EN)
- Lithuania (EN)
- Luxembourg (FR/NL/EN)
- Malta (EN)
- Montenegro (EN)
- Netherlands (NL)
- North Macedonia (EN)
- Norway (NB)
- Poland (PL)
- Portugal (PT)
- Romania (RO)
- Russia (RU)
- Serbia (SR)
- Slovakia (SK)
- Slovenia (SL)
- Spain (ES)
- Sweden (SV)
- Switzerland (DE/FR)
- Ukraine (UK)
- United Kingdom (EN)
- North America
- South & Central America